LCN2 and colitis: In particular, it was found that GDNPs 2 treatment could reduce lipocalin-2 (Lcn-2) fecal levels in mice with DSS-induced colitis, suggesting an anti-inflammatory role of these nanoparticles; Lcn-2 is considered a biomarker for intestinal inflammation [56].